← All Intensity Therapeutics, INC filings

Intensity Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
INTS
Intensity Therapeutics, INC
10-K: Intensity Therapeutics 2025 10-K: Clinical Progress & Funding Challenges
Intensity Therapeutics' latest 10-K details clinical advancements for its lead cancer drug INT230-6, alongside significant operating losses and ongoing funding needs.
NASDAQ
INTS
Intensity Therapeutics, INC
10-K: Intensity Therapeutics Reports 2024 Financial Results, Highlights Clinical Progress
Intensity Therapeutics files its 10-K, reporting on its financial performance for 2024 and outlining key clinical trial advancements.
NASDAQ
INTS
Intensity Therapeutics, INC
10-K: Intensity Therapeutics Files 10-K, Highlights Progress in Cancer Treatment Pipeline
Intensity Therapeutics' 10-K filing details clinical trial progress, manufacturing advancements, and future plans for their novel cancer treatment technology.